Cytokinetics, Incorporated Common Stock CYTK
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T05:55:10.980Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:21:43.969754347Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T05:55:00.888510+00:00
Cytokinetics, Incorporated Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 63.06 | 66.5% | 11.2% | 52.63 | 69.6% | 9.5% |
| 25Δ | 61.96 | 66.3% | 9.6% | 53.49 | 71.3% | 8.5% |
| 30Δ | 60.87 | 64.0% | 8.0% | 54.35 | 73.1% | 7.5% |
| 35Δ | 59.85 | 61.6% | 6.6% | 55.21 | 74.6% | 6.6% |
| 40Δ | 59.10 | 59.4% | 5.7% | 56.07 | 75.7% | 5.9% |
| 45Δ | 58.35 | 57.2% | 4.7% | 56.93 | 76.7% | 5.1% |
| 50Δ | 57.59 | 55.0% | 3.8% | 57.81 | 77.8% | 4.4% |
| 55Δ | 57.09 | 51.8% | 3.2% | 58.76 | 78.9% | 3.8% |
| 60Δ | 56.63 | 48.5% | 2.7% | 59.71 | 80.0% | 3.3% |
| 65Δ | 56.17 | 45.1% | 2.2% | 61.20 | 88.2% | 2.9% |
| 70Δ | 55.71 | 41.8% | 1.6% | 62.95 | 97.7% | 2.6% |
| 75Δ | 55.24 | 38.4% | 1.1% | 64.74 | 101.7% | 2.1% |
| 80Δ | ||||||
20Δ
- Pseudo strike
- 63.06
- IV
- 66.5%
- B/E move
- 11.2%
- Pseudo strike
- 52.63
- IV
- 69.6%
- B/E move
- 9.5%
25Δ
- Pseudo strike
- 61.96
- IV
- 66.3%
- B/E move
- 9.6%
- Pseudo strike
- 53.49
- IV
- 71.3%
- B/E move
- 8.5%
30Δ
- Pseudo strike
- 60.87
- IV
- 64.0%
- B/E move
- 8.0%
- Pseudo strike
- 54.35
- IV
- 73.1%
- B/E move
- 7.5%
35Δ
- Pseudo strike
- 59.85
- IV
- 61.6%
- B/E move
- 6.6%
- Pseudo strike
- 55.21
- IV
- 74.6%
- B/E move
- 6.6%
40Δ
- Pseudo strike
- 59.10
- IV
- 59.4%
- B/E move
- 5.7%
- Pseudo strike
- 56.07
- IV
- 75.7%
- B/E move
- 5.9%
45Δ
- Pseudo strike
- 58.35
- IV
- 57.2%
- B/E move
- 4.7%
- Pseudo strike
- 56.93
- IV
- 76.7%
- B/E move
- 5.1%
50Δ
- Pseudo strike
- 57.59
- IV
- 55.0%
- B/E move
- 3.8%
- Pseudo strike
- 57.81
- IV
- 77.8%
- B/E move
- 4.4%
55Δ
- Pseudo strike
- 57.09
- IV
- 51.8%
- B/E move
- 3.2%
- Pseudo strike
- 58.76
- IV
- 78.9%
- B/E move
- 3.8%
60Δ
- Pseudo strike
- 56.63
- IV
- 48.5%
- B/E move
- 2.7%
- Pseudo strike
- 59.71
- IV
- 80.0%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 56.17
- IV
- 45.1%
- B/E move
- 2.2%
- Pseudo strike
- 61.20
- IV
- 88.2%
- B/E move
- 2.9%
70Δ
- Pseudo strike
- 55.71
- IV
- 41.8%
- B/E move
- 1.6%
- Pseudo strike
- 62.95
- IV
- 97.7%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 55.24
- IV
- 38.4%
- B/E move
- 1.1%
- Pseudo strike
- 64.74
- IV
- 101.7%
- B/E move
- 2.1%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 52.43% | |
| 52.65% | |
| 52.52% | |
| 52.31% | |
| 51.95% | |
| 53.31% | |
| 54.79% | |
| 50.63% | |
| 51.68% | |
| 53.93% |
Biotechnology
DBVT
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered…
More →DFTX
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New…
More →DMAC
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis,…
More →DNA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide…
More →DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is…
More →DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and…
More →